myirislogo
04 July, 2015 13:57 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
Hindalco In 110.55 0.54
State Bank O 268.85 0.54
Reliance 1006.75 0.35
Tata Stl 300.95 1.13
Icici Bank 314.35 0.45
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Cipla Limited
Cipla Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs and Formulations
BSE:500087NSE:CIPLABloomberg:CIPLA@INReuters:CIPL.BO
Market Lot: 1Face Value: 2ISIN Demat: INE059A01026
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
18-JUN-15 Cipla, leading drug maker, announced that nomination and remuneration committee of the company allotted 1,30,548 equity shares of Rs 2 each pursuant to exercise of the stock options by the option grantee under Employee Stock Option Scheme 2013-B. 08-JUN-15 Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that it has been granted process patent from the ...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Stempeutics gets Japan process patent for its novel stem cell drug Stempeucel  -IRIS 08-Jun-15
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Mar-2015(12)31-Mar-2014 (12)31-Mar-2013 (12)
Net sales 96832.9090349.5080153.70
Other Income1479.102802.802291.30
Total Income98312.0093152.3082445.00
Cost of goods sold81704.7073907.6060832.80
OPBDIT16607.3019244.7021612.20
PAT11810.9013883.4015071.10
Gross Block---
Equity capital1605.901605.801605.80
EPS (Rs.)-17.2918.77
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-21.06 - 26.0316.02 - 23.18
Debt / Equity (x)---
Operating margin (% of OI)16.920.726.2
Net margin (% of OI)12.014.918.3
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Mumbai Central
Mumbai
Maharashtra-400 008
PHONE
(022) 2309 5521 / 2302 5272
FAX
(022) 2300 8101
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer